New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GE;DELL;GSK;AZN;BEN;AAPL From The Last 14 Days
Check below for free stories on GE;DELL;GSK;AZN;BEN;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
August 21, 2014
10:34 EDTAAPLOptions Update; August 21, 2014
Subscribe for More Information
10:03 EDTAAPLActive puts at CBOE
Subscribe for More Information
10:02 EDTAAPLActive calls at CBOE; AAPL C HPQ
Active calls at CBOE; AAPL 8/22/14 100 & 100, C Jan 55, HPQ 8/29/14 36
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
09:37 EDTAAPLActive equity options trading on open
Subscribe for More Information
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
16:01 EDTAAPLOptions Update; August 20, 2014
Subscribe for More Information
15:35 EDTGSKGlaxoSmithKline receives FDA approval for Arnuity Ellipta in the U.S.
Subscribe for More Information
13:46 EDTAAPLVerizon looking to build app store, The Information says
Verizon (VZ) is looking to partner with other companies to build an app store, according to The Information. Verizon's app store would compete with Google (GOOG) and Apple (AAPL), which already sell smartphone software, The Information noted. Reference Link
11:44 EDTGSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
11:15 EDTAAPLGT Advanced retreats after analyst downgrades stock
Shares of sapphire maker GT Advanced (GTAT) are falling after research firm CLSA downgraded the stock in a note to investors today. The firm cited concerns about increased costs associated with the company's deal with Apple as the main reason for the downgrade. WHAT'S NEW: GT Advanced's costs associated with its deal to supply sapphire to Apple are being impacted by low yields, CLSA analyst Mark Heller wrote after speaking with strategic consulting firm Yole Développement. Lower yields will reduce the amount of sapphire that GT Advanced can produce for Apple, and will negatively affect GT’s profit margins, explained Heller. He believes that GT Advanced's risk/reward ratio is balanced at current levels, and downgraded his rating on the shares to Underperform from Outperform. However, he raised his price target on the shares to $19 from $18. PRICE ACTION: In late morning trading, GT Advanced fell 2% to $18.
09:38 EDTAAPL, AAPLGT Advanced downgraded to Underperform from Outperform at CLSA
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FOLD TSLA TWTR WHX FB TM NFLX X EOG
08:30 EDTGSKPernix closes acquisition of Treximet
Subscribe for More Information
08:29 EDTGSKPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:11 EDTGEGE Healthcare Life Sciences announces new U.S. headquarters in MA
Subscribe for More Information
08:04 EDTGSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
06:28 EDTAAPLApple could delay iWatch until 2015, FT Alphaville reports
Subscribe for More Information
August 19, 2014
17:31 EDTGEGE plans to invest $3.5B in aircraft engine unit, Nikkei says
General Electric plans to invest $3.5B in its aircraft engine business over the five years to 2017, as it looks to boost production, says Nikkei. Reference Link
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use